DMDavid O. McGregor

David O. McGregor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David O. McGregor has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Kelvin L. Lynn

    From the Cardioendocrine Research Group (R.W.T., C.F., T.Y., A.M.R., G.N.) and the Department of Nephrology (D.O.M., K.L.L.), Christchurch Hospital, Christchurch, New Zealand

    4 shared publications
  • Adrian L. Buttimore

    2 shared publications
  • M. Gary Nicholls

    From the Cardioendocrine Research Group (R.W.T., C.F., T.Y., A.M.R., G.N.) and the Department of Nephrology (D.O.M., K.L.L.), Christchurch Hospital, Christchurch, New Zealand

    2 shared publications
  • A. Mark Richards

    From the Cardioendocrine Research Group (R.W.T., C.F., T.Y., A.M.R., G.N.) and the Department of Nephrology (D.O.M., K.L.L.), Christchurch Hospital, Christchurch, New Zealand

    1 shared publication
  • Brett Shand

    1 shared publication
  • Christopher Frampton

    From the Cardioendocrine Research Group (R.W.T., C.F., T.Y., A.M.R., G.N.) and the Department of Nephrology (D.O.M., K.L.L.), Christchurch Hospital, Christchurch, New Zealand

    1 shared publication

Latest Publications

  • Hypotensive and Natriuretic Actions of Adrenomedullin in Subjects With Chronic Renal Impairment

    by David O. McGregor, Richard W. Troughton, Christopher Frampton, Kelvin L. Lynn, Timothy Yandle, A. Mark Richards, M. Gary Nicholls

    —Plasma levels of adrenomedullin are increased in chronic renal failure. The significance of this finding is uncertain, because the biological effects of adrenomedullin in renal impairment are unknown. Therefore, we studied the effects of adrenomedullin infusion in subjects with chronic renal impairment. Eight males with IgA nephropathy and plasma creatinine of 0.19±0.03 mmol/L (mean±SEM) were studied in a vehicle-controlled crossover design. Each subject was studied twice; subjects were administered either adrenomedullin at a low dose and then a high dose (2.9 and 5.8 pmol/kg per minute, respectively, for 2 hours each) or a 4-hour vehicle control (Hemaccel), in random order, on day 4 of controlled metabolic diets. Adrenomedullin infusion achieved plasma adrenomedullin concentrations in the pathophysiological range after the low (31.2±5.1 pmol/L) and high (47.4±4.3 pmol/L) dose, and plasma cAMP was increased. Compared with vehicle control, high-dose adrenomedullin increased peak heart rate (+21.7±3.3 bpm, P P 10 mm Hg ( P P P <0.05) with low-dose adrenomedullin, whereas creatinine clearance was stable, and proteinuria tended to decrease. In subjects with chronic renal impairment due to IgA nephropathy, adrenomedullin infusion lowered blood pressure, stimulated sympathetic activity and renin release, and caused diuresis and natriuresis. Adrenomedullin may have a role in modulating blood pressure and kidney function in renal disease.


  • AUTONOMIC DYSFUNCTION AND AMBULATORY BLOOD PRESSURE IN RENAL TRANSPLANT RECIPIENTS

    by David O. McGregor, Claire Olsson, Kelvin L. Lynn

    Abnormal circadian blood pressure (BP) rhythm (nondipping) and autonomic dysfunction are both common in end-stage renal disease (ESRD). It is not known whether these abnormalities are related or if they are associated with greater left ventricular hypertrophy. Nineteen renal transplantation (RT) recipients, aged 22-67 years, who were transplanted at least 12 months (1-29 years) previously, were studied with 24-hr ambulatory blood pressure monitoring (ABPM). Autonomic function was tested by automated analysis of heart rate variations and echocardiography was used to estimate left ventricular mass index (LVMI). Thirteen patients (68%) were nondippers. Although seven (37%) patients had significant parasympathetic dysfunction, this was not related to dipper status. Neither abnormality showed a tendency to diminish with time after RT. Systolic hypertension, diagnosed by ABPM, occurred in 5% of patients during the awake period and in 52% during sleep, whereas diastolic hypertension occurred in 47% when awake and in 63% when asleep. Awake systolic BP was the strongest predictor of LVMI (r=0.7, P<0.001), and was considerably better than systolic BPs recorded at the clinic (r=0.48, P<0.05). Nondipping is common after RT but is not related to the degree of autonomic dysfunction. These findings suggest that autonomic dysfunction is not a major contributor to nondipping in ESRD. In RT patients, ABPM is a more sensitive measure of hypertension and a stronger predictor of LVMI than clinic BP.


  • A Comparative Study of Blood Pressure Control with Short In-Center versus Long Home Hemodialysis

    by David O. McGregor, Adrian L. Buttimore, Kelvin L. Lynn, M. Gary Nicholls, David L. Jardine

    We conducted a randomized crossover trial to establish, within patients, whether long-slow hemodialysis (HD) was associated with better blood pressure (BP) control than standard HD. Nine home HD patients, not on antihypertensive drugs, were dialyzed to the same eKt/Vurea and target weights for 6–8 h (LD) at home and for 3.5–4.5 h (SD) in the dialysis center 3 times weekly in randomized sequence, with each phase lasting 8 weeks. Ambulatory BP, bioimpedance, neurohormones and autonomic function were measured in each phase. Pre- and postdialysis systolic, ambulatory systolic and diastolic BP were all higher with SD than with LD and intradialysis hypotension was more common. Weight, ECF volume and neurohormones did not differ between treatments. Muscle sympathetic activity was increased in both phases and cardiac sympathetic activity tended higher during SD. These findings suggest that additional factors to ECF volume may contribute to the superior BP control produced by long-slow HD.


  • A Controlled Trial of the Effect of Folate Supplements on Homocysteine, Lipids and Hemorheology in End-Stage Renal Disease

    by David McGregor, Brett Shand, Kelvin Lynn

    Elevated plasma homocysteine (Hcy), dyslipidemia and hemorheological abnormalities all occur commonly in end-stage renal disease (ESRD) and are recognized risk factors for arteriosclerosis. To study the effect of folate supplementation on these factors we conducted a randomized controlled trial. Thirteen hemodialysis (HD) and 8 continuous ambulatory peritoneal dialysis (CAPD) patients received either 5 mg folic acid daily or placebo for 3 months. After 1 and 3 months, fasting blood samples were taken for Hcy, lipid profile, blood and plasma viscosity, red blood cell (RBC) osmotic fragility, plasma fibrinogen concentration and in vivo platelet aggregability. At baseline, the CAPD patients had a higher mean plasma fibrinogen concentration than the HD patients and they also tended to have higher mean plasma viscosity. Folate-treated patients showed marked increases in RBC folate and an average decrease in plasma Hcy concentration of 33%. Mean total cholesterol, LDL cholesterol and triglyceride concentrations decreased significantly in the CAPD patients who took folate. Folate had no significant effect on hemorheology. In conclusion, folate supplements in ESRD reduce plasma Hcy concentrations and may improve lipid profiles. In our patients, hemorheological abnormalities were more marked in patients on CAPD than in those on HD and were not improved by folate supplementation.


  • Home hemodialysis: Excellent survival at less cost, but still underutilized

    by David O. McGregor, Adrian L. Buttimore, Kelvin L. Lynn